One of the oldest challenges in oncology is creating a drug that kills cancer cells while sparing healthy ones. Peptides are ...

Debiopharm is advancing its ADC platform with a focus on proprietary bispecific ADCs and innovative payloads. By leveraging its proven drug development expertise, the company aims to accelerate ...

MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...

Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep® (belantamab mafodotin) -- a critical new treatment option for Canadians living ...